Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

POWERED BY OPEN COLLABORATIVE RESEARCH

The End ME/CFS Project encompasses OMF funded and facilitated research conducted within six ME/CFS Collaborative Research Centers (CRCs). OMFCA’s guiding strategy focuses on open, collaborative research so that precise diagnostic tools and life-changing treatments can be available to people with related chronic complex diseases as soon as possible.

Funding an internationally-based research network instead of single researchers ensures the stability and collaboration essential for an outcomes-focused, transparent, and multi-pronged approach to finding answers

OMF COLLABORATIVE NETWORK

The six CRCs are working collaboratively to build a repository of data about ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID-19.

This data is essential to develop diagnostic technologies, understand the molecular basis of the diseases, and uncover effective diagnostic tools and treatments.

ME / CFS Collaborative
Research Center

at Stanford

The Ronald G. Tompkins Harvard
ME / CFS Collaboration

at Harvard Affiliated Hospitals
Major Research Initiatives

With oversight from OMF’s Boards of Directors and Scientific Advisory Board, the following research projects further OMFCA’s Strategic Goals to improve the diagnosis and treatment of ME/CFS, Post-treatment Lyme Disease, and related chronic, complex diseases. 

Current

Previous

Post COVID-19 to ME/CFS Research Plan

The current COVID-19 pandemic offers an unprecedented opportunity to understand how a viral infection may convert to ME/CFS in some patients.

The six ME/CFS Collaborative Centers have begun a unique,  extensive, in-depth longitudinal molecular study following COVID-19 patients. Their shared goal is to determine the pathways involved in maintaining long-term symptoms in some patients,  possibly converting to ME/CFS. They seek to learn about these pathways so as to develop biomarkers, novel drug targets,  new treatment, and prevention strategies.

OMF–Funded Research Publications
  1. Neurovascular Dysregulation and Acute Exercise Intolerance in ME/CFS: A Randomized, Placebo-Controlled Trial of Pyridostigmine by Phillip Joseph, MD, Rosa Pari, MD, Sarah Miller, BS, Arabella Warren, BS, Mary Catherine Stovall, BS, Johanna Squires, MSc, Chia-Jung Chang, PhD, Wenzhong Xiao, PhD, Aaron B. Waxman, MD, PhD, David M. Systrom, MD
  2. The underlying sex differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic Fatigue Syndrome by Natalie Thomas, Caroline Gurvich, Katherine Huang, Paul R Gooley, Christopher W Armstrong
  3. Drawing on Findings From Critical Illness to Explain Myalgic Encephalomyelitis / Chronic Fatigue Syndrome by Jonas Bergquist and Dominic Stanculescu
  4. Lessons From Heat Stroke for Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by Dominic Stanculescu, Nuno Sepúlveda, Chin Leong Lim and Jonas Bergquist
  5. A Comprehensive Examination of Severely Ill ME/CFS Patients,”  by Ronald W. Davis, PhD and Wenzhong Xiao, PhD, Stanford Collaboration
  6. Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for ME/CFS, by Jonas Bergquist, MD, PhD, Uppsala Collaboration
  7. Phase 1 study to access safety, tolerability, pharmacokinetics09, and pharmacodynamics of kynurenine in healthy volunteers, by Jonas Bergquist, Uppsala Collaboration 
  8. Insights from Invasive Cardiopulmonary Exercise Testing by David Systrom, MD, Harvard Collaboration
  9. Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie ME/CFS by Jonas Bergquist, MD, PhD, Uppsala Collaboration
  10. Microfluidic Point-of-Care Testing: Commercial Landscape and Future Directions by Ronald W. Davis, PhD and Amit K. Saha, Stanford Collaboration
  11. Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology by Alain Moreau, PhD, Montreal Collaboration
  12. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients by Jonas Bergquist, Uppsala Collaboration
  13. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid by Jonas Bergquist, Uppsala Collaboration
  14. The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS by Robert D. Phair, PhD and Ron Davis, PhD, Stanford Collaboration
  15. A Nanoelectronics-blood-based diagnostic biomarker for ME / CFS by Rahim Esfandyarpour, PhD and Ronald W. Davis, PhD, Stanford Collaboration
  16. Red Blood Cell Deformability is diminished in patients with Chronic Fatigue Syndrome, by Anand Ramasubramanian, PhD and Ronald Davis, PhD, Stanford Collaboration
  17. Metabolic features of chronic fatigue syndrome by Robert Naviaux, MD, PhD, Stanford Collaboration
Help us accelerate this urgent research!